Ethinylestradiol/norethindrone acetate vaginal - Pfizer

Drug Profile

Ethinylestradiol/norethindrone acetate vaginal - Pfizer

Alternative Names: CI 1001

Latest Information Update: 12 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Alkylated estrogenic steroids; Hormonal contraceptives; Norpregnatrienes; Norpregnenes; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pregnancy

Most Recent Events

  • 12 Feb 2015 Discontinued - Phase-III for Pregnancy (Prevention) in USA (Vaginal) prior to February 2015
  • 21 Jun 2000 Warner-Lambert has merged with Pfizer
  • 31 Mar 2000 Phase-III clinical trials for Contraception/Pregnancy (Prevention) in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top